Tirzepatide + Vitamin B6 — Compounded for Individual Biology
A dual-receptor injectable formulation designed to regulate blood sugar, reduce appetite, and support sustainable weight loss — compounded specifically for your patient's biology.
Tirzepatide
GLP-1 and GIP dual receptor agonist clinically demonstrated to reduce body weight and improve glycemic control. Acts on two key metabolic pathways simultaneously for superior efficacy.
Vitamin B6 (Pyridoxine)
Included for its potential role in reducing nausea associated with GLP-1 therapy. Also supports neurological health and energy metabolism throughout treatment.
Standard Concentration: Tirzepatide (10 mg/mL) + Vitamin B6 (10 mg/mL)
| Step | Dose | Units | Volume | Duration | Vial Size | Concentration |
|---|---|---|---|---|---|---|
| 1 — Initiation | 2.5 mg | 25 units | 0.25 mL | 4 weeks | 1 mL | 10 mg/mL |
| 2 | 5 mg | 50 units | 0.5 mL | 4 weeks | 3 mL | 10 mg/mL |
| 3 | 7.5 mg | 75 units | 0.75 mL | 4 weeks | 2 mL | 10 mg/mL |
| 4 | 10 mg | 100 units | 1.0 mL | 4 weeks | 2 mL | 10 mg/mL |
| 5 | 12.5 mg | 125 units | 1.25 mL | 4 weeks | 3 mL | 10 mg/mL |
| 6 — Maximum | 15 mg | 150 units | 1.5 mL | 4 weeks | 3 mL | 10 mg/mL |
Higher Concentration: Tirzepatide (20 mg/mL) + Vitamin B6 (10 mg/mL)
| Step | Dose | Units | Volume | Duration | Concentration |
|---|---|---|---|---|---|
| A | 7.5 mg | 37.5 units | 0.375 mL | 4 weeks | 20 mg/mL |
| B | 10 mg | 50 units | 0.5 mL | 4 weeks | 20 mg/mL |
| C | 12.5 mg | 62.5 units | 0.625 mL | 4 weeks | 20 mg/mL |
| D — Maximum | 15 mg | 75 units | 0.75 mL | 4 weeks | 20 mg/mL |
Starting dose determined by the prescribing provider. Titration increases if tolerated.
Dose adjustments should target the lowest effective dose to minimize side effects and support long-term adherence.
- If a patient experiences persistent GI symptoms at a given dose, the prescriber may hold the current dose for an additional 4-week cycle before escalating.
- Dose reduction (stepping back one level) is clinically appropriate when side effects impair adherence or quality of life.
- All dose changes must be initiated by the prescribing provider. Genesis does not adjust doses independently.
* Ondansetron ODT 4mg may be co-prescribed as needed for nausea management. Consult prescriber.
Tirzepatide is a dual GLP-1 and GIP receptor agonist. By activating both incretin pathways simultaneously, it offers a differentiated mechanism compared to GLP-1-only agonists:
- GLP-1 pathway: Slows gastric emptying, increases satiety, improves insulin secretion in a glucose-dependent manner.
- GIP pathway: Enhances fat metabolism, supports beta-cell function, and may contribute to greater weight loss efficacy.
- Combined effect: Superior glycemic control and weight reduction compared to single-pathway agents in clinical trials.
Vitamin B6 (Pyridoxine) is included for its role in amino acid metabolism, neurotransmitter synthesis, and its potential to mitigate nausea — one of the most common side effects of GLP-1 receptor agonist therapy.
Contraindications:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known hypersensitivity to tirzepatide or any component of the formulation
Warnings & Precautions:
- Pancreatitis — discontinue if suspected
- Gallbladder-related events
- Hypoglycemia risk, especially when combined with insulin or sulfonylureas
- Renal impairment — monitor in patients with kidney disease
- GI adverse reactions including nausea, diarrhea, vomiting, constipation, abdominal pain
Common Side Effects: Nausea (most common, typically decreases over time), diarrhea, decreased appetite, vomiting, constipation, dyspepsia, abdominal pain.
- Store refrigerated at 2°C to 8°C (36°F to 46°F)
- Do not freeze. Do not use if product has been frozen.
- Protect from light. Store in original packaging until use.
- Allow vial to reach room temperature before injection.
- Discard after the beyond-use date listed on the label.
- The medicine should be fine for 5 days from the shipping date at temperatures up to 105 degrees Fahrenheit.
What is compounded tirzepatide?
Compounded tirzepatide is a custom-prepared version of the active pharmaceutical ingredient (API) tirzepatide, formulated in a 503A-licensed pharmacy according to a prescriber's specific order. It is not a commercially manufactured product.
Why is Vitamin B6 included?
Vitamin B6 may help reduce nausea, which is one of the most common side effects of GLP-1 receptor agonist therapy. It also supports neurological health and energy metabolism.
How do I inject it?
Tirzepatide is administered as a subcutaneous injection, typically in the abdomen, thigh, or upper arm. Rotate injection sites. Your prescriber or pharmacist will provide detailed injection instructions.
How quickly will I see results?
Response varies by individual. Most patients notice appetite changes within the first few weeks. Meaningful weight loss typically occurs over several months of consistent use with lifestyle modifications.
Can I take other medications with it?
Inform your prescriber of all current medications. Some drugs may interact or require timing adjustments due to delayed gastric emptying caused by GLP-1 agonists.
Partner with Genesis Compounding
A 503A-licensed compounding partner built for telehealth and physician practice workflows. Download your onboarding documents below to get started.
Fax completed forms to 385-855-1221 or email pharmacy@genesiscompounding.com